Chronic Hepatitis B (CHB) remains a significant global health challenge, necessitating effective antiviral therapies. Adefovir Dipivoxil (CAS 142340-99-6) has played a notable role in the therapeutic landscape for this condition. For pharmaceutical R&D scientists and procurement specialists, understanding its clinical profile, mechanism of action, and comparative effectiveness is crucial when evaluating treatment options and sourcing strategies.

Mechanism of Action and Clinical Efficacy

Adefovir Dipivoxil is an orally administered prodrug of adefovir, classified as an acyclic nucleotide analog reverse-transcriptase inhibitor. Once metabolized to its active diphosphate form, it competitively inhibits hepatitis B virus (HBV) DNA polymerase, leading to the termination of viral DNA chain synthesis. This action effectively suppresses viral replication. Its approval in 2002 marked a significant advance, particularly for patients with lamivudine-resistant HBV, as it possessed a higher barrier to resistance than earlier nucleoside analogs. While newer agents like tenofovir disoproxil fumarate (TDF) and entecavir (ETV) have since demonstrated superior efficacy in head-to-head trials, Adefovir Dipivoxil remains a relevant option in certain therapeutic contexts or resource-limited settings, often as a generic formulation.

Safety Profile and Considerations for Procurement

A key consideration for Adefovir Dipivoxil is its safety profile, particularly the risk of nephrotoxicity. Careful monitoring of renal function is essential for patients undergoing treatment. Boxed warnings also highlight the potential for severe acute exacerbations of hepatitis upon discontinuation, HIV resistance in co-infected patients, and the class-wide risk of lactic acidosis and severe hepatomegaly. For procurement managers, understanding these safety aspects is vital, as it influences the selection of compliant manufacturing processes and quality control measures for the intermediate. Ensuring the highest purity, typically 99.0% MIN, and sourcing from GMP-certified facilities is paramount.

Market Position and Sourcing from China

While newer antiviral agents have largely supplanted Adefovir Dipivoxil as first-line therapy in many developed countries, it continues to be manufactured and utilized, particularly as a cost-effective generic option. The global market for pharmaceutical intermediates, including Adefovir Dipivoxil, is significantly influenced by manufacturers in China. These suppliers often provide a combination of competitive pricing and large-scale production capabilities, making them attractive partners for companies seeking to buy this intermediate. Prioritizing suppliers with strong quality assurance systems and adherence to international pharmacopoeial standards (USP, BP, EP, FCC) is key.

Engage with a Trusted Supplier

As a dedicated manufacturer and supplier of pharmaceutical chemicals, we offer high-quality Adefovir Dipivoxil (CAS 142340-99-6) that meets rigorous industry standards. We are committed to providing reliable supply chains and competitive pricing for our clients. If you are involved in the R&D or procurement of antiviral agents for chronic hepatitis B, we invite you to connect with us to discuss your requirements and explore how our products and services can support your critical manufacturing needs.